Inês Amorim Monteiro Barbosa

Inês Amorim Monteiro Barbosa

Auto-generated profile, based on publicly available information

Inês Amorim Monteiro Barbosa

Disease area Oncology, Novartis Biomedical Research, Basel, Switzerland. 4

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in Blood
Verified
Journal Article
Closed access
PDF file
JSJohannes Schmoellerl
Johannes Schmoellerl
IBInês A. M. Barbosa
Inês A. M. Barbosa
MMMartina Minnich
Martina Minnich
FAFlorian Andersch
Florian Andersch
LSLeonie Smeenk
Leonie Smeenk
JZJohannes Zuber
Johannes Zuber
Chromosomal rearrangements involving the MDS1 and EVI1 complex locus (MECOM) on chromosome 3q26 define an aggressive subtype of acute myeloid leukemia (AML) that is associated with chemotherapy resistance and dismal prognosis. Established treatment regimens commonly fail in these patients, therefore, there is an urgent need for new therapeutic concepts that will require a better understanding of the molecular and cellular functions of the ecotropic viral integration site 1 (EVI1) oncogene. To characterize gene regulatory functions of EVI1 and associated dependencies in AML, we developed experimentally tractable human and murine disease models, investigated the transcriptional consequences of EVI1 withdrawal in vitro and in vivo, and performed the first genome-wide CRISPR screens in EVI1-dependent AML. By integrating conserved transcriptional targets with genetic dependency data, we identified and characterized the ETS transcription factor ERG as a direct transcriptional target of EVI1 that is aberrantly expressed and selectively required in both human and murine EVI1–driven AML. EVI1 controls the expression of ERG and occupies a conserved intragenic enhancer region in AML cell lines and samples from patients with primary AML. Suppression of ERG induces terminal differentiation of EVI1-driven AML cells, whereas ectopic expression of ERG abrogates their dependence on EVI1, indicating that the major oncogenic functions of EVI1 are mediated through aberrant transcriptional activation of ERG. Interfering with this regulatory axis may provide entry points for the development of rational targeted therapies.

14 October 2021 in Blood
Verified
Journal Article
Open access
PDF file
EKE. van der Kouwe
E. van der Kouwe
GHGerwin Heller
Gerwin Heller
ACA. Czibere
A. Czibere
JPJ. A. Pulikkan
J. A. Pulikkan
CAC. Agreiter
C. Agreiter
PSPhilipp Bernhard Staber
Philipp Bernhard Staber
The blood system serves as a key model for cell differentiation and cancer. It is orchestrated by precise spatiotemporal expression of crucial transcription factors. One of the key master regulators in the hematopoietic systems is PU.1. Reduced levels of PU.1 are characteristic for human acute myeloid leukemia (AML) and are known to induce AML in mouse models. Here, we show that transcriptional downregulation of PU.1 is an active process involving an alternative promoter in intron 3 that is induced by RUNX transcription factors driving noncoding antisense transcription. Core-binding factor (CBF) fusions RUNX1-ETO and CBFβ-MYH11 in t(8;21) and inv(16) AML, respectively, activate the PU.1 antisense promoter that results in a shift from sense toward antisense transcription and myeloid differentiation blockade. In patients with CBF-AML, we found that an elevated antisense/sense transcript and promoter accessibility ratio represents a hallmark compared with normal karyotype AML or healthy CD34+ cells. Competitive interaction of an enhancer with the proximal or the antisense promoter forms a binary on/off switch for either myeloid or T-cell development. Leukemic CBF fusions thus use a physiological mechanism used by T cells to decrease sense transcription. Our study is the first example of a sense/antisense promoter competition as a crucial functional switch for gene expression perturbation by oncogenes. Hence, this disease mechanism reveals a previously unknown Achilles heel for future precise therapeutic targeting of oncogene-induced chromatin remodeling.

16 May 2024 in Cancer Discovery
Verified
Journal Article
Open access
IBIros Barozzi
Iros Barozzi
NSNeil Slaven
Neil Slaven
ECEleonora Canale
Eleonora Canale
RLRui Lopes
Rui Lopes
IBInês Amorim Monteiro Barbosa
Inês Amorim Monteiro Barbosa
LMLuca Magnani
Luca Magnani
Only a handful of somatic alterations have been linked to endocrine therapy resistance in hormone-dependent breast cancer, potentially explaining ∼40% of relapses. If other mechanisms underlie the evolution of hormone-dependent breast cancer under adjuvant therapy is currently unknown. In this work, we employ functional genomics to dissect the contribution of cis-regulatory elements (CRE) to cancer evolution by focusing on 12 megabases of noncoding DNA, including clonal enhancers, gene promoters, and boundaries of topologically associating domains. Parallel epigenetic perturbation (CRISPRi) in vitro reveals context-dependent roles for many of these CREs, with a specific impact on dormancy entrance and endocrine therapy resistance. Profiling of CRE somatic alterations in a unique, longitudinal cohort of patients treated with endocrine therapies identifies a limited set of noncoding changes potentially involved in therapy resistance. Overall, our data uncover how endocrine therapies trigger the emergence of transient features which could ultimately be exploited to hinder the adaptive process. Significance: This study shows that cells adapting to endocrine therapies undergo changes in the usage or regulatory regions. Dormant cells are less vulnerable to regulatory perturbation but gain transient dependencies which can be exploited to decrease the formation of dormant persisters.

17 June 2026
Verified
Other
Open access
IBIros Barozzi
Iros Barozzi
NSNeil Slaven
Neil Slaven
ECEleonora Canale
Eleonora Canale
RLRui Lopes
Rui Lopes
IBInês Amorim Monteiro Barbosa
Inês Amorim Monteiro Barbosa
LMLuca Magnani
Luca Magnani
Supplementary Table S17: Downstream analyses considering only the SIDV inferred genetic alterations with predicted impact on function and stratifying them by cancer-cell fraction (CCF) increase and decrease in metastatic samples. S17.1: summary of the results of the statistical tests performed to identify differences in the predicted impact of mutations stratified by change in CCF in metastatic samples compared to matched primary. The fraction of variants predicted as pathogenic and either showing an increase or a decrease in CCF (+- 0.1) was compared to that of those showing no change. P-values for the indicated features are shown (Chi-squared test). S17.2: similarly, the distribution of the predicted molecular effects of variants in the three groups (increase, decrease or no change in CCF) were compared using the Kruskal-Wallis test. S17.3: like S13.3 but testing for the enrichment of mutations with both computationally predicted pathogenic effects and a certain CCF increase or decrease in metastatic samples, that also show a certain behavior in SIDP.

17 June 2026
Verified
Other
Open access
IBIros Barozzi
Iros Barozzi
NSNeil Slaven
Neil Slaven
ECEleonora Canale
Eleonora Canale
RLRui Lopes
Rui Lopes
IBInês Amorim Monteiro Barbosa
Inês Amorim Monteiro Barbosa
LMLuca Magnani
Luca Magnani
Supplementary Figure S15. Validation of SIDP via chemical perturbation.

4 September 2024
Verified
Other
Open access
IBIros Barozzi
Iros Barozzi
NSNeil Slaven
Neil Slaven
ECEleonora Canale
Eleonora Canale
RLRui Lopes
Rui Lopes
IBInês Amorim Monteiro Barbosa
Inês Amorim Monteiro Barbosa
LMLuca Magnani
Luca Magnani
Supplementary Table S16: Downstream analyses considering only the SIDV inferred genetic alterations with predicted impact on function. S16.1: results of the binomial enrichment test. SID regions overlapping at least 2 SNVs predicted as pathogenic are included. Along with genomic coordinates (hg38) the total number of SNVs as well as the number of predicted pathogenic SNVs overlapping the region are indicated. The p-value and the q-value (after Benjamini-Hochberg correction) of the binomial test are indicated, along with annotation to the closest gene. The 63 regions considered for further analyses are highlighted in red. S16.2: same as S13.1 but considering all the regions assigned to the genes annotated to the same ontological terms together. The number and identity of the genes contributing to the overlap are indicated, along with p-value of the binomial test, and the q-value (after Benjamini-Hochberg correction). Statistically significant terms (q-value <= 0.05) are highlighted in red. S16.3: results of the analyses testing for the enrichment of mutations (either SNVs, short INDELs, or both; mutation_type column) with computationally predicted pathogenic effects in the sets of regions also showing a certain behavior in SIDP (CRISPRi_hit_type column). Observed and expected overlap are indicated, along with the odds ratio and the p-value (Chi-squared test).